HLB bioStep Co.,Ltd. (278650.KQ)

3,550.00 -20.00 (-0.56%) At close: 03:30PM KST

HLB bioStep Co.,Ltd.

38 Academy-ro
79beon-gil Yeonsu-gu
Incheon 22014
South Korea
82 32 833 8899
https://hlbbiostep.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
In-Sung Jeong	Co-Chief Executive Officer	N/A	N/A	N/A
Mr. Do-Hyung Kim	Co-Chief Executive Officer	N/A	N/A	1980

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local infection model, PK study, chemical, transgenic animal, osteoblast-like cell line screening, bone formation marker, and biomarker. The company also provides pharmacokinetic/toxico study, toxicology study, and biological drug; and toxic/clinical pathology services. The company was formerly known as KNOTUS Co.,Ltd. The company was founded in 2012 and is based in Incheon, South Korea.

Corporate governance

HLB bioStep Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.